Sarepta Therapeutics shares jumped over 36% on Tuesday after the company said it had received FDA approval to restart ...

US stocks gave up earlier gains on Tuesday as investors digested a wave of corporate earnings and economic data, while ...

-U.S. futures for the S&P 500 and Dow Jones Industrial Average rose 0.1% and Nasdaq futures gained 0.3%. Earnings will come today from Boeing, Spotify, United Health, Procter & Gamble, Visa and PayPal ...

Wall Street traders left stocks at all-time highs while the dollar climbed the most since May, with a tariff deal between ...

This regulatory relief, combined with several other compelling catalysts, creates a pathway for the stock to potentially ...

Despite all the buzz around Sarepta and concerns about Elevidys, industry watchers aren’t convinced this current controversy ...

Sarepta Therapeutics shares surged more than 30% before the bell on Tuesday, as analysts said the resumption of U.S. shipments for its muscular gene therapy partially removes financial headwinds and ...

The FDA has lifted its hold on Elevidys for ambulatory patients, after asking Sarepta to pause the treatment following three deaths.

Sarepta Therapeutics ( NASDAQ: SRPT) was upgraded to Neutral from Underweight at J.P. Morgan as it sees FDA's Elevidys hold removal recommendation in ambulatory patients as a clear win.

Shares of beleaguered drugmaker Sarepta Therapeutics jumped in afterhours trading Monday after the company said it would ...

US stocks pared earlier gains on Tuesday, but kept a bid for more records in sight, as investors combed through a fresh rush ...